Challenges of Diagnosing Antibody-Mediated Rejection: The Role of Invasive and Non-Invasive Biomarkers
Kidney transplantation is the best treatment modality for end-stage kidney disease, leading to improvement in a patient’s quality and quantity of life. With significant improvements in short-term outcomes, prolonging long-term allograft and patient survival remain ongoing challenges. The ability to...
Main Authors: | Sambhavi Krishnamoorthy, Yousuf Kyeso |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1648-9144/57/5/439 |
Similar Items
-
Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation
by: Farah Abuazzam, et al.
Published: (2023-07-01) -
Urinary Exosomal Cystatin C and Lipopolysaccharide Binding Protein as Biomarkers for Antibody−Mediated Rejection after Kidney Transplantation
by: Mi Joung Kim, et al.
Published: (2022-09-01) -
The Proteome of Antibody-Mediated Rejection: From Glomerulitis to Transplant Glomerulopathy
by: Bertrand Chauveau, et al.
Published: (2022-02-01) -
Early Exposure of Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab—A Preliminary Study
by: Capucine Arrivé, et al.
Published: (2023-11-01) -
Pathophysiology of Rejection in Kidney Transplantation
by: Christina L. Tamargo, et al.
Published: (2023-06-01)